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1 Introduction 
The provision of services for drug users has grown dramatically in most European 
countries over the past decade. In the initial half of the decade the threat of HIV had a 
significant impact on the overall direction of policy priorities and service expansion. By the 
latter part of the decade a broader mix of health and criminal justice imperatives has come 
to dominate the policy agenda. The challenge for policy is to find a sound and rational 
policy mix between public health and criminal justice priorities and to develop new and 
innovative methods of integrating these approaches in a manner that has been rigorously 
evaluated and has clear evidence of effectiveness. 
As with other areas of health care delivery, the challenge for services is to ensure equity of 
access, high quality and efficient services, and provide evidence that the services deliver 
the impact that they aim for. 
Drug misuse is a complex psychosocial problem which requires a multifaceted response. 
There is a special challenge in constructing appropriate multidisciplinary and multi-sectoral 
responses that effectively incorporate differing priorities and result in teams that have 
clarity of purpose, high morale and effective management and outcomes. 
1.1 Terms of Reference 
¾ An external review of the Drug Services in the Eastern Health Board was requested 
in June 1999 and the key terms of reference agreed were “having regard to the 
national policies within which services are provided”. 
¾ To review the current policies and practices in relation to the provision of services 
for drug users in the Eastern Health Board area. 
¾ To review the development of services form the starting point of the previous 
review conducted in 1995. 
¾ To review the service provision and the service mix. 
¾ To review and make recommendations on items such as:- 
(i) Movement of clients from Centres to clinics and general practice. 
(ii) Case management and client focussed approach in EHB service. 
(iii) Staffing and skill mix in the services provided by the EHB. 
¾ To review partnerships with other agencies. 
¾ To review practices of EHB linked services for drug users. 
¾ To comment on service response in the EHB area in the context of trends and 
practices elsewhere. 
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1.2 Methods 
Michael Farrell was contracted as an external consultant with a special expertise on the 
organisation and delivery of drug services. Claire Gerada is a general practitioner with 
major policy interest and expertise on the delivery of drug treatment as a part of Shared 
care. John Marsden is a principle investigator on the National Treatment Outcome 
Research Project. 
Key Policy Makers, Teams and individuals, including GP coordinators, Consultant 
Psychiatrists, Area Managers, Counsellors, Education Officers, Outreach Workers, Nurses, 
voluntary sector agencies and individuals, were interviewed as part of a key informant 
process. Site visits were conducted to a wide range of services to gain an overall picture of 
the spread of services. 
The aim of the interviews and site visits was to ascertain how key strategic and operational 
policies had been implemented. It was not the aim or the terms of reference to conduct 
detailed individual site operational evaluation. 
2 Background to current service provision 
There has been a remarkable degree of activity and expansion within the services in the 
EHB over the past four to five years. The EHB identified that there was a need for urgent 
expansion of services and were also clear that there was a need to develop services that 
were local and tailored to the needs of particular communities. To this end a programme of 
service expansion was embarked on that is probably one of the more innovative 
community drug service programmes in Europe. It has taken the core of the evidence on 
the effectiveness of methadone maintenance and attempted to develop a range of services 
to ensure higher levels of treatment access. This has resulted in a major expansion in the 
levels of provision of methadone treatment with over 4000 individuals in treatment by mid 
1999. In addition, this also achieved a distribution of services into small community 
satellite clinics and a range of other community based services. This innovation directly 
addressed the issue of community resistance to the delivery of drug treatment services 
through insistence that such services would be focussed for designated geographic patches. 
Thus the services have expanded from three locations to over 50 locations in the space of 
five years. Over the past decade the budget for the service has increased more than 10 fold. 
This level of rapid expansion is a major achievement that involves an all-consuming level 
of managerial and administrative involvement. The services are now likely to require an 
opportunity for consolidation and planning for the next level of development. The 
development of services has occurred against a background of ongoing growth and 
development of drug problems and a high political profile on drug  
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problems. For the future integrity of the services there is a critical need for close 
collaborative working with broader preventative interventions. 
Current level of drug problems is difficult to ascertain, but there is robust data to indicate 
that the heroin problem is primarily confined to the Eastern Health Board Region of the 
country. However if international experience is to be replicated it is likely that heroin use 
will eventually extend itself into other metropolitan areas and also into deprived rural 
localities. 
The Two Reports of the Ministerial Task Force on Measures to Reduce the Demand for 
Drugs looked at the problems of both heroin and other drug misuse and concluded that 
heroin abuse was by far the most serious aspect of the drug problem confronting not only 
the statutory authorities but Irish society in general at the time. 
As a result of this the Ministerial Task Force recommended the establishment of Local 
Drugs Task Forces in the areas most severely affected by a combination of deprivation and 
drug dependence. A National Drugs Strategy Team with a policy and an operational 
component is in place as part of the overall coordination of local drug task forces. 
3 Evolution of Current Services 
Drug problems are a relatively new phenomenon, which have appeared over the past three 
decades and have continued to grow over that period. The nineteen fifties and early sixties 
were periods of minimal non-prescribed drug problems. The sixties saw the growth of an 
international youth culture and counterculture, which was strongly associated with 
psychoactive drug use. However, even at that period the levels of problems were extremely 
modest by today’s standards. 
In a city the size of Dublin the growth of the drug problem has had a high profile even 
from its earliest stage. 
The first services established in the EHB area were established through the Department of 
Health. This was the Drug Treatment and Advice Centre in Jervis St Hospital in 1969, 
which had in-patient and outpatient facilities. The Coolmine therapeutic community in 
North County Dublin was opened in 1973. Subsequently, a range of other voluntary sector 
bodies established some community and residential facilities. Jervis St was transferred to 
Trinity Court in the late 1980s and the in-patient facilities were transferred to Beaumount 
Hospital. For much of the 1980s the overall capacity of the system to respond to problem 
drug users was primarily located in a small number of facilities which experienced great 
difficulty in meeting treatment demand. The mid to late nineteen eighties saw the 
development and expansion of the voluntary sector agencies providing non-residential 
facilities, including needle exchange programmes and other health and harm reduction 
activities. 
The mid eighties also saw substantial development of EHB activity in drug services with 
the development of drug services in Baggot Street, Cherry Orchard  
and in Amiens Street. Much of this activity was in response to the major concerns around 
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the spread of HP/ through injecting drug use. At the same time a range of community 
workers were developed including outreach workers, community addiction counsellors and 
educational officers. 
The Strategic Objectives of the AIDS/Drugs Service, in line with Ministerial Task Force 
Reports on the Measures to Reduce the Demand for Drugs are to provide in conjunction 
with voluntary agencies where appropriate: 
¾ Education and prevention programmes. 
¾ Services aimed at delivering advice and harm minimisation programmes to drug 
misusers not in contact with services including advice on safer drug use, ways to 
reduce the risk of HP/, Hepatitis transmission, safer sex and advice on good health. 
¾ Treatment programmes which have as their objective in the short term control of the 
drug misusers addiction within the context of the long-term aim of a return of the 
drug misuser to a drug free lifestyle. 
¾ Aftercare and rehabilitation programmes to assist misusers access education, 
training or employment opportunities. 
¾ Evaluation of the various service responses to ensure maximum effectiveness. 
In 1999 Drugs services were part of the Health Promotion, Mental Health, Addiction and 
Social Development Programme which the Programme Manager has overall responsibility 
for the service development and delivery. There are three geographical regions headed by 
an Area Operational Manager, Consultant Psychiatrist, GP Coordinator and Liaison 
Pharmacist. Head of disciplines report to the Area Operations Manager. The overall budget 
for the entire programme in 1999 was 100.660 million pounds with 17.5 million being 
allocated to the AIDS/Drugs services but this includes capital development costs. Thus, the 
AIDS/Drugs service is allocated nearly 15% of the overall programme costs. 
In 1996 the Government established a Ministerial Task Force on Measures to Reduce the 
Demand for Drugs and this task force made recommendations to deal with the heroin 
problem through a strategic, locally based, integrated response in the areas where the 
problem was most severe. New national and local structures were put in place with the twin 
objectives of involving communities in the process and ensuring a more coordinated 
approach at national and local levels. These committee structures included a Cabinet Drugs 
Committee (subsequently re-constituted into a wider Committee on Social Inclusion), a 
National Drugs Strategy Team (comprising representatives of relevant Government 
Departments and Statutory agencies and individuals from the voluntary community sectors 
to bring a voluntary community perspective to the work of the Team), and Local Drugs 
Task Forces (13) in areas where drug misuse was most prevalent. 
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3.1 Current Needs Assessment 
Over the past 5 years there has been substantial activity to determine the level of problem 
drug misuse in the EHB area and in Ireland as a whole. As in other parts of Europe social 
survey data indicate a substantial growth in the use of non-opiate drugs such as Cannabis, 
Ecstasy, Amphetamine, LSD. It is reasonable to estimate that the growth in experimental or 
occasional drug use will result in a growth in the number of regular drug users and as a 
result of regular drug use increased numbers of individuals with problematic or dependent 
drug use. The relationship of such broad population patterns of use and the evolution of 
hard core heroin use, poly-drug use and severe chronic opiate dependence is not clear. The 
existence of a core of chronic opiate addicts provides the framework for a sustained opiate 
problem and necessitates appropriate treatment provision as part of an overall humanitarian 
approach to this condition that carries high levels of social, physical and psychological 
morbidity and also increased mortality. In addition, the third party costs of drug use such as 
theft and other forms of criminality need to be ameliorated through the provision of 
treatment interventions. 
A recent capture-recapture study conducted has estimated that there are approximately 
13,000 heroin addicts in Dublin. Such studies are useful at providing rough estimates but 
there are serious methodological problems in using such figures as reliable baseline 
denominators in broader needs assessment approaches because of the width of the 
confidence intervals in such studies and the paucity of data on which to base case 
ascertainment. For this reason such studies need to be combined with other forms of multi-
enumerator methods to gain data that can be used to provide more confident interpretation 
for service planning and development. 
Despite such limitations current service data and data from prison studies indicate that 
there is a continuing shortfall between the demand for treatment and its current level of 
supply. Such shortfall can have significant impact on the overall functioning and rationale 
of service organisation where services are modified or adapted to meet immediate local 
circumstances and responses. Figures quoted for prevalence of opiate dependence range 
from 0.25% to 0.5% but the clustering of problems in high deprivation localities can result 
in much higher rates in some high deprivation localities. 
There is a need to be clear that counting of prevalence within the population does not 
necessarily equate with actual treatment need and it is the estimates of the numbers in the 
population who are actually in need of clinical treatment that is critical for service 
planning. 
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4 The development of services from the starting point of the previous review conducted 
in 1995 
The previous report conducted by Farrell and Buning recommended that the services 
develop a broad range of prevention, treatment and rehabilitation services in order to meet 
the complex demands of the target population. In a short space of time the EHB, in the face 
of substantial community opposition has developed and diversified its level of treatment 
provision for drug addicts at a breathtaking rate. The pace and scale of change must have 
presented major logistical and manpower challenges and the readiness, flexibility and 
adaptability of the workers to this pace of change is very impressive. It is likely that the 
challenge of putting so many new services in place over a short period of time has 
absorbed considerable energy of the management and of the different teams. 
The pace of change more latterly has been particularly pressurised with the introduction of 
the legislative change and the implementation of the methadone protocol with the transfer 
of large volumes of cases into the EHB service from private general practice. This appears 
to have been achieved with a minimum of disruption despite the scale of the change. 
The EHB area has been effectively divided into three regions and the responsibilities of the 
senior staff including consultant psychiatrists, GP co-ordinators, Liaison Pharmacists and 
Outreach Workers. Organisational restructuring has divided the activities of the EHB into 
three regions and this process of change was underway during the review period. This 
change is likely to consolidate the sectorisation of the AIDS and Drugs Services. As the 
three-area structure evolves there will be a budget for common services and there is a need 
for these to be integrated within community services. There will be a need for rules and 
protocols to ensure equal access for all community services where shared services exist. 
The introduction of the Methadone Protocol has enabled the formal organisation of the 
relationship between primary care and secondary care delivery of methadone treatment. At 
the same time the Pharmacy Coordinators have developed a large network of community 
pharmacists who are trained and experienced in the delivery of services to drug misusers. 
Over 50 different treatment sites have been established with a mixture of larger on-site 
services such as Castle St and St James Hospital to smaller satellite clinics in North, South 
and West County Dublin. 
The commencement of the methadone bus has provided an opportunity to deliver 
methadone treatment in communities where there has been strong opposition to the 
establishment of treatment clinics. The mobile bus has also operated as part of the outreach 
and needle exchange service. 
There has been substantial investment in senior trained staff through the appointment of 
two new consultant psychiatrists and a network of GP coordinators. 
 
The appointment of a training officer and an assistant training officer has enabled the 
development of a training strategy. 
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Virtually all of the key recommendations from the previous report have been implemented 
with the exception of two things. There has been limited progress in the implementation of 
a comprehensive needle exchange programme. There has been limited links between the 
DRUGS/AIDS service and other related services such as alcohol treatment services. 
The prison services remain underdeveloped and subject to criticism. There is a need for an 
integrated mental health and drugs addiction treatment service for the prison that ensures 
continuity with community based programmes. Some of the more recent projects within 
the criminal justice system will require development of a detailed needs assessment of 
effective responses to problems within the prisons and a subsequent development of 
services to meet such a needs analysis. 
5 The current policies and practices in relation to the provision of services for drug 
users in the Eastern Health Board area. 
5.1 Clinic Performance 
The development of a range of clinics should allow for good performance 
measurement where benchmarks or standards can be set which allow for 
performance management evaluation (PME). Issues such as the case-mix of the 
treatment population would need to be accounted for. There are critical parameters 
such as amount of heroin use as indicated by urine positivity, social adjustment as 
indicated by numbers returning to employment, rehabilitation indices such as the 
numbers in training programmes or other parameters that are determined by the 
priorities of the clinic or of the locality. 
One example of comparison across a number of clinics indicates, substantial 
variation on some of the measures of urine drug testing. However, overall, it must be 
stated that where reduction of heroin use has been the key priority there is a striking 
similarity with high levels of opiate negative urines in all of the five clinics reported 
here. 
The following table shows the results of urine test for opiates, benzodiazepines and 
tricyclics carried out in five addiction clinics across the EHB area. The data are 
based on tests conducted over a four-month period in 1999. The total number of tests 
and the percentage of positive and negative results are shown per clinic and an 
aggregate overall figure combining tests from all five clinics is also provided. 
 
 
 
 Clinic 1 Clinic 2 Clinic 3 Clinic 4 Clinic 5 Aggregated
clinic total 
Opiates % Positive 31% 30% 27% 30% 33% 30%
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% Negative 69% 70% 73% 70% 67% 70%
Total 7558 3173 4657 5277 4237 24902
% Positive 65% 46% 72% 76% 73% 65% 
% Negative 35% 54% 28% 24% 27% 35%
Benzodiaz- 
epines 
Total 6816 3171 4649 1418 2088 18142
% Positive 18% 3% 17% 9% 18% 14%
% Negative 82% 97% 83% 91% 82% 86%
Tricyclics 
Total 7476 3170 4655 5218 1934 22453
 
It is appropriate to state that by international standards of assessment of methadone clinics 
the rates of both positive and negative tests indicate clinics that are operating to a very high 
standard of performance on this particular parameter. However on the negative side the 
high rates of benzodiazepine positivity indicate a major problem of poly drug misuse 
which requires urgent and concerted attention. 
It is important to note that the urinalysis data as currently gathered provides robust data to 
indicate that the current treatment programmes have managed to effect approximately a 
70% reduction in heroin consumption on aggregate in those attending treatment. Such a 
reduction in heroin use has been reported to be associated with a similar reduction in 
offending behaviour and it would be reasonable to estimate that the treatment for these 
individuals has effectively reduced levels of criminal offending by a similar 70%. 
A number of the satellite clinics informally reported rates of 40% plus returning to work, 
such levels of beginning or returning to work indicate the positive work climate that exists 
in Dublin but is also very striking as evidence of successful social habilitation or 
rehabilitation. It is worth further exploring these variations to determine whether 
programme or clinic characteristics are associated or facilitate these positive outcomes. 
Rates of 30% return to work are remarkable by current international standards and full 
attention should be paid to this phenomenon. A process should be put in place to properly 
monitor and document the performance of the clinics on this parameter. Such an exercise 
should formally establish through documented and objective procedures the social welfare 
and occupational status of individuals in treatment. The EHB should consider choosing a 
range of key performance parameters and ensure that data on these parameters are collected 
and analysed across the entire service. 
In the previous report considerable reservation was expressed about the value of expending 
substantial resource on urine testing. Such an activity  
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continues to be a high item of expenditure in the manner in which it is organised currently, 
with substantial staff time spent gathering and processing such tests. Within the time scale 
of this review it was not possible to determine how much and how consistently such results 
were used in day to day management that would justify the expenditure. However, on the 
available urine test data the results are impressive and if these could be correlated with 
other parameters of progress they would appear to provide some reasonable justification 
for continuing this approach. However urine testing should be viewed as one dimension of 
an overall approach to monitoring and quality control within treatment programmes. 
Currently, the costs of urine testing in both laboratory costs and human resources costs are 
disproportionately high and needs to be reviewed. It is recommended that clinical leaders 
explore options for a range of quality and performance measures beyond urine testing and 
that the resource be more broadly spread. Such an approach could include detailed 
systematic monitoring of a range of outcome measures with central support to assist in the 
processing of such data. Overall, it is desirable to cut back on expenditure on urine testing 
and invest in a broader range of quality controls activities. 
5.2 Primary Care Services and the treatment of drug misusers 
The drug misuse service involving primary care has been designed and planned in a 
systematic manner to produce a delivery of care that is innovative and has been one of the 
major developments of the past five years. This has been done with clear commitment and 
major time investment of a broad range of individuals but in particular has been 
championed by a number of key general practitioners. 
The service arose primarily out of the need to expand the overall capacity for methadone 
maintenance treatment in Dublin and also from a situation of inappropriately high 
prescribing by a small number of GPs treating drug users; many of whom lacked the 
necessary training and support to do this sort of work safely. There were concerns around 
drug diversion. Overall, there was a limited number of GPs involved in the care of drug 
users and the work was seen as unattractive and poorly paid by the main stream of primary 
care. 
Through a series of negotiations between the Health Board, the Irish Medical Organization 
and the RCGP (I) a service was developed to help overcome some of these issues. The 
current organizational structure, therefore, was designed in order to overcome the historical 
difficulties in both managing these patients and in providing support, expertise, training 
and resources to GPs involved in this work. 
The service, training requirements, accreditation criteria and payment structure has in the 
most part been primary care led which has both advantages and disadvantages attached to 
it. 
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The movement of patients from specialist clinics into primary care is an important and core 
part of the future development of the service in its ability to create capacity and to develop 
a tiered service where high intensity treatment is delivered within the secondary care 
service and ongoing stabilised individuals are managed within primary care. To date there 
has been limited movement and the explanations for this are not altogether clear. It is 
possible that the specialist services are not being proactive enough in moving stabilised 
patients on. It is also possible that there has not been an adequate concentration of 
promoting and supporting the involvement of level 1 GPs as much of the patient load has 
moved to GP co-ordinators (see further in section on Primary Care). 
There has been a well conducted evaluation of the movement of one cohort of methadone 
maintained patients from the specialist clinics into primary care which demonstrated that 
the group of stabilised patients, as defined by non use of opiates and other drugs other than 
those prescribed, could be equally well managed within a primary care setting. This would 
seem to indicate that a minimum of 25% could be transferred into primary care settings if 
use of both opiate and benzodiazepines are taken into account. This would result in a 
substantial ongoing capacity problem unless more stability can be achieved in a larger 
cohort of patients. It would seem reasonable to estimate that up to 50% might achieve such 
as status but currently it would appear that this figure is closer to 30% if the data from the 
urine tests is interpreted conservatively. 
Between January 1999 and October 1999, 205 new patients went into primary care 
services. While this appears modest as a number, it is a significant proportionate increase 
in numbers in primary care. However, it is clear that there needs to be a substantial increase 
in this if the capacity problem across the service is to be adequately addressed. There were 
119 general practitioners involved in the protocol at the end of October 1999, but of these 
71 practitioners had less than 5 patients with nearly half having less than three patients. 
There is a need to expand the number of practitioners and encourage and support these 
practitioners to manage a reasonable workload of patients. 
Within this approach there is also a need to consider briefer management approaches as 
exemplified in the Fortune House Project, where detoxification over a shorter period of 
time is delivered. Such an approach would allow for people with a shorter history of opiate 
dependence to attempt to achieve a drug free status and it would also be clear that multiple 
failed attempts at such an approach should lead to consideration of more sustained 
maintenance treatment. A twin track approach that combines detoxification with 
maintenance would also ensure some individuals could have shorter term contact with 
services and would in effect create some treatment capacity by having a degree of 
throughput for one stream of patients. 
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There is an important issue of deciding where to locate primary care services and it should 
be a key goal of all services providers to link the individual patient and their family into a 
local practitioner where continuity of care can be developed. Such an approach would also 
prevent some of the dispensing clinics from dispensing a wide range of therapeutic 
medication that should ideally be dispensed in a more generic community setting unless 
there are specific indications for clinic dispensing. 
There is a need to review the roles and supports for GP coordinators to ensure that 
adequate time and support is available for the coordinators to complete their main function. 
To this end consideration should be given to some coordinators taking on a salaried post 
that would enable appropriate time for providing support and liaison to level one GPs with 
the aim of increasing overall levels of activity of level one GPs. 
There is also a need to make a clearer distinction between the skills of the level one and the 
level 2 practitioners. 
Finally there is a need to develop a mechanism to ensure that families in particular the 
children of drug treatment patients have access to primary care services. 
5.3 Case management and client focussed approach in EHB service 
There is a range of professionals involved in teams in a number of different settings and 
there are important differences in many of these settings as to how they are managed and 
organised. Overall, it is clear that in most of these settings that the teams have managed 
rapidly increasing work loads with enthusiasm, skill and commitment. However, there is 
considerable duplication of function and overlap of function within teams when it comes to 
the management of individual clients. Consideration should be given to the development of 
a key worker system where a single individual worker in the team would be responsible for 
the treatment of an individual who would be subject to overall review and would be 
reviewed and discussed within the team supervision process on at least a three monthly 
basis. Involvement of other team members prior to this would be on the basis of using 
additional assessment or intervention skills as appropriate to the case. Such an approach 
would be predicated on the assumption that the service was organised in a fashion where 
each of the team members was trained to deliver the core treatment and each member of 
the team would carry a case load of 30 to 40 patients. In a well-run team this would also 
include shared knowledge of more complex cases in order to ensure consistency of team 
approach to such individuals. Such an approach appears to be in operation in some clinics 
already. 
The diversification of skill base might enable the services to expand capacity by moving 
beyond the situation where patients are seen on a regular basis by the clinic doctor for short 
periods of time. Obviously, some of the clinic capacity is also determined by dispensing 
capacity and issues of local impact of numbers attending clinics. The development of clear 
treatment protocols and prescribing protocols would require medical  
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involvement at the stage of assessment and initiation of treatment, at review and at a stage 
where medication change occurred that was not within the service protocol or where 
concerns for other aspects of physical or mental health required further assessment. 
It is possible that within such a system that clinical nurse specialists could develop new 
roles and responsibilities and there could be further exploration of ways to develop and 
expand the capacities of the multiprofessional, multidisciplinary team. 
5.4 Staffing and skill mix in the services provided by the EHB 
The other possible options that could be considered are the use of care coordinators or case 
managers. Such individuals could be tasked with overseeing the delivery of multi-modal 
treatment from a range of professionals and also assessing the impact of such treatment 
against baseline measures. Such an approach might assist in ensuring better coordination 
and integration of services. Of course, such an approach would be contingent on the 
availability of a range of services and on the ready access of such services for these 
patients. The development of new Criminal Justice Based interventions such as drug courts 
also make the use of such Case managers timely. If Case managers has access to FAS 
employment programmes, Housing support, Family interventions, including parenting 
classes and parenting support activities and other structured day programme activities as 
well as other medical and psychiatric services, there is some preliminary work to indicate 
that such an approach can improve treatment outcomes. 
It is open to exploration to consider how some of the current coordinator role could be 
evolved into a new care coordinator role. The development of such a role could be piloted 
to ensure that such a function did not simply add a new bureaucratic tier to an already 
complex system. 
Other studies indicate that much of the change that is likely to occur within a treatment 
programme is achieved at the early stage of entry into treatment and that the expectations 
of outcome and goals of treatment need to be firmly set at the early stage of treatment. If 
such a finding were correct it would provide a basis for setting very clear structures and 
expectations around the type of interventions delivered in the first period of treatment. 
There is considerable interest in developing manual guided approaches to treatment at this 
stage in order to ensure that this early and critical phase of treatment is delivered to a 
reasonable and consistent standard by a range of professionals who have been trained in 
this approach. Such an approach might allow for training of some General Assistants as 
well as counsellors, nurses, social workers and doctors in a fashion that could attempt to 
ensure that the team maximised its use of manpower resources in delivering structured 
treatment. 
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There is limited use of clinical psychology input and consideration should be given to 
developing a tier of clinical psychology that would develop the skills of the 
multidisciplinary team including the medical staff and work to regularly update and 
introduce new and innovative therapeutic techniques as they are developed. 
5.5 Review practices of EHB linked services for users drug 
The ongoing waiting lists put considerable pressure on existing services and can distort 
existing services. A clear example of this is the current use of the methadone bus, which 
seems to function for two purposes. One is to pick up individuals who are awaiting 
treatment but the other is to pick up individuals who have been subject to sanctions and 
assigned to low dose methadone from the bus for an interim period. The mixing of these 
two populations seems undesirable but has been generated by service exigencies. 
A midwife/obstetric liaison service has been established which provides important links 
between primary care services, drug services, social services and other relevant agencies. 
This is an important area for monitoring and ensuring that the links fostered in this setting 
be explored for replication in other settings. 
Given the integrated nature of EHB services there seems to be a strong case for substantial 
expansion in this form of liaison/shared care model into primary care, general mental 
health services, child and adolescent psychiatric services, hepatology services, criminal 
justice agencies. At a local level case managers or liaison workers could provide a key role 
in ensuring that a combination of community and statutory resources are mobilised in order 
to achieve maximum treatment and rehabilitation impact. 
There is considerable concern about the initiation of very young users and there is a need 
for a child and adolescent focus in some services. The services are currently primarily adult 
focussed and there is a need to consider the practice and professional issues involved in 
working with underage users. These issues are particularly relevant where needle exchange 
and methadone prescribing is being provided. There is a need for a clear policy and 
recommendations for practice to ensure that staff understand fully the complex possible 
medico-legal and childcare protection legal issues involved in managing vulnerable 
youngsters. Such issues could be usefully explored with Youth services and Child and 
Adolescent services to ensure that appropriate child and family focussed practices are 
adopted within the services. 
5.6 Needle Exchange Schemes 
The Needle exchange provision within Dublin is patchy and not very comprehensive. It is 
understandable that there is substantial sensitivity and community resistance to such 
services. However the limited amount  
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of facilities for the safe disposal of used injecting equipment is an environmental hazard 
that should be directly addressed. A broader range of secure disposal facilities should be 
developed that are well geographically distributed. Part of the decision on locating such 
facilities could be guided by a mapping of locations that currently have substantial 
environmental health problems due to syringe litter. Pharmacists could also provide 
disposal facilities but are generally reluctant to do so for occupational health and safety 
reasons. 
There is also a need for a network of needle exchange facilities that could provide sterile 
syringes as well as collect used equipment. It is possible that pharmacies have an important 
role to play in this and could be engaged without encountering major issues of community 
resistance that may be likely with the development of other facilities. 
Merchants Quay play an important role in needle exchange provision but because of the 
limited amount of overall provision there is a real risk that such a service draws individuals 
from a wide geographic network together in a manner that is not desirable for a range of 
reasons. 
It is also noteworthy that currently the Outreach workers provide a range of syringe 
exchange services. In the absence of other provision this service is critical to the current 
geographic spread of needle exchange provision. 
A well evaluated pilot study of needle exchange via community pharmacy would be a 
rational and practical way forward which would provide useful information about 
processes and problems in establishing such a service. 
5.7 Pharmacy Services 
There has been very major developments in the delivery of services to drug users through 
pharmacy based services over the past five years. The Pharmacy co-ordinators faced a 
substantial challenge in developing community pharmacy based services and has achieved 
remarkable success. Overall, there are now 152 pharmacies in the EHB area with 
methadone patients. There are a small number of services with extremely high numbers. 
Some of this is due specific local provision, however, it is a cause for serious concern as it 
is likely to result in problems of community resistance and local nuisance over a period of 
time and likely to be an unsustainable mode of community service provision with 
intermittent crises. In a survey conducted by the Liaison Pharmacist it is reported that 
nearly 70% of respondent pharmacists were prepared to supervise methadone self-
administration on site at their premises and approximately on third said they were not. Half 
of the pharmacists who were willing to supervise self-administration reported that they had 
a private area suitable for such activity. The pharmacists reported good links with local 
prescribers, but also reported poor feedback with the same services. 
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The issues facing the liaison pharmacist are similar to the challenges facing the most 
professionals in the EHB service which is that of major expansion of workload, 
diversification of role and function and heavy commitment to face to face work in addition 
to the co-ordinating function. There is a need for a clear phase of consolidation within 
pharmacy services. There is a large spend now within the drugs budget and there is a need 
for further analysis to ensure that services are organised in a professional and cost effective 
manner. It is likely that manpower and recruitment will remain a challenge and this has 
important implications for quality and continuity of service. 
There are also issues arising of the primary care involvement within the specialist clinics 
where some services appear to have pharmacies involved in a range of generic medication 
dispensing. It is desirable that this be streamlined and demarcated so that such primary care 
prescribing be clearly delineated. There is a need for clear policies about the range of 
medication that can be prescribed within specialist clinics if the specialist pharmacist 
function is to be maintained and developed. There is a clear need for ongoing training and 
support and there may be room for developing innovative modes of communication 
between the clinicians in the drug services and the pharmacies that would improve the 
overall function of the team. Better integration between these professionals is likely to pay 
substantial dividends in the quality and coherence of the local service. 
5.8 Non opiate type drug assessment and treatment responses 
The EHB to date has been heavily focussed on developing services and facilities for those 
who are chronically dependent on heroin and other opiates. There is now a need to broaden 
the base of services available and to consider how briefer types of interventions could be 
developed that would be accessible for young people before they have progressed to 
chronic heroin addiction. A broader community based treatment programme where the 
workers have a capacity to conduct assessments and provide advice and treatment for 
problems ranging from long term cannabis use, MDMA, cocaine and benzodiazepines is 
required. To date some of this has been provided by counsellors, outreach workers and 
others. There is a need to formalise this approach and it is possible that such an approach 
could be provided on a larger geographical scale than current clinic provision. Such an 
approach could be based on a direct access system and problems of a more complex nature 
could be referred to more local services. 
The challenge is to construct a framework of a service that will be able to adapt to 
changing patterns of drug abuse over time and than can achieve maximum access and 
utilization of the skills of existing staff. If these activities are linked with existing services 
it will provide existing staff with opportunities to work with individuals who have better 
levels of social functioning and are less entrenched in their drug habits. Such  
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services should be identifiably separate but organisationally should be closely integrated 
with the whole service. 
Some aspects of this might be linked to developing services for people with alcohol 
problems and developing methods to ensuring more integration between alcohol and drug 
services. 
5.9 Development and Provision of Rehabilitation, both day programme and residential 
services 
There is now a relatively high level of provision of in-patient and residential rehabilitation 
services in Dublin. The outcome study conducted on a cohort from Cuan Dara indicates 
moderately good impact on what is clearly a difficult to treat population. The development 
of a down stream service to integrate with the shorter stay unit is a welcome development. 
This service because of the duration of stay is likely to have a heavy demand on it and is 
likely to experience serious difficulty in meeting expectations. 
Overall, there is a need for better links between the community based day programmes, and 
the inpatient and residential services. 
There is considerable interest in the use of Naltrexone as part of a community 
reinforcement strategy where detoxification is conducted in an inpatient setting and 
ongoing intensive support is provided within a day programme setting. Particular interest 
has been expressed in linking this to Criminal Justice Approaches to treatment but there is 
also the possibility of exploring the use of Naltrexone as an adjunctive support after a 
shorter stay period within the inpatient unit. 
Currently the Voluntary Sector Residential services continue to be key providers of 
services. Many of these services are long standing with experienced and knowledgeable 
staff, however, there is a need for these different services to meet and to develop a more 
cohesive voice about the role of the residential sector in the overall provision of services. 
Such joint activities could also explore issues of training and establishing mutually agreed 
standards for service provision, m particular, there is a need for a more coherent approach 
to how these services link into the broader range of community services. 
Overall, there is a need for careful linkage between monitoring, evaluation and training 
programmes and research programmes. Monitoring could include new and innovative 
approaches to assessing the nature and content of the individual treatment sessions through 
video taped sessions, which are then reviewed as part of the supervision process. Such an 
approach could be linked to improving the quality and practical usefulness of the content of 
sessions through the development of more structured manually based approaches for 
interventions for both drug and alcohol problems. 
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 5.10 Day Programmes and the Criminal Justice System 
There has been substantial investment in day programmes and a number of day 
programmes are run in different locations in the city. Some of these programmes have been 
highly innovative and also have obtained a high profile through the skillful use of media 
resources. The use of such structured facilities for providing clear structure in the early 
phase of treatment seems desirable but may conflict with some of the existing overall aims 
of these day programmes. 
Because of the complex nature of many drugs related problems there are many agencies 
where the consequences of chronic drug use and dependence impact. The most obvious and 
costly is that of the prison system and of the probation service. To date the EHB has placed 
substantial resource within prisons through the allocation of substantial specialist and 
general medical time. Internationally there is much change afoot as services in many 
countries strive to find models that integrate the treatment services with the criminal justice 
services. 
Both the Health Board and the prisons need to explore further the development of 
multidisciplinary teams to develop integrated and holistic care that emphasises continuity 
and aims to tackle chronic recidivism. Overall, there is a need for more structured linkages 
between specific programmes and the prison services. It is recommended that ongoing 
work is progressed to formally structure the linkages between prisons and community 
based programmes and between the rehabilitation programmes and the other community 
based programmes. 
The key challenge will be to develop good quality, accessible community based treatment 
that individuals can be linked into on release from prison. There has been substantial 
investment in day programmes and some of the day programmes are models of their kind 
that have developed an international profile and standing. However, the numbers being 
processed through appear to make the unit cost of these programmes high. There is a need 
to see how these programmes can be linked with methadone treatment as part of the new 
criminal justice strategy either as alternatives to prison and importantly if legally feasible 
as an early prison release option which attempts to bring high offending chronic recidivists 
into contact with the treatment rehabilitation system. 
FAS report that they are making available a substantial number of training slots for drug 
addicts in treatment. Such an offer seems a valuable opportunity. There is a need to ensure 
that such an offer is actively pursued and that the use of such services are monitored to 
determine what impact these training programmes have and to determine what are the 
strategies required to encourage up take of such programmes. There should be an annual 
audit and report on the numbers using these FAS facilities and targets should be set for the 
services for referral of clients into these FAS services. 
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There is a continued problem in the level of need and the level of provision within prisons. 
This presents a challenge to all services and requires a system where the community 
services have the capacity to rapidly access individuals into treatment and to develop a 
system of continuity between community based and prison services that would allow 
methadone provision within prisons. 
5.11 Education and Prevention Services 
One of the key aims of the National Drug Strategy and of the EHB services is to ensure 
that there is an adequate range of provision of drug prevention strategies in place. This 
process has been assisted by the development of the Local and National Drug Task Forces, 
which have a particular focus on education and rehabilitation. The challenge facing 
community based prevention strategies is the wide number of potential stakeholders and 
difficulty of mobilising key individuals to participate in such activities. Within the 
structure of current activities the local task force coordinators have a potentially critical 
role to play in ensuring that all resources are mobilised. Both the Education Officers and 
the Outreach workers have a remit for prevention. Both groups of professionals are faced 
with a very broad task and there is a case for narrowing the remit of these activities so that 
the professionals are provided with a clearer more focussed task, with a clear mode of 
implementation and a clear mechanism by which they can assess the impact of their 
activities. The Local Task Forces would appear to be an important focal point for 
developing clear and integrated local prevention strategies where the roles of the different 
educational and health professionals are well delineated. The challenge of drug prevention 
should not be underestimated and in the context of health promotion the EHB should 
consider drawing a clear boundary on its remit which should be more targeted towards high 
risk and vulnerable individuals. Currently children and adolescents at high risk for alcohol 
and drug problems are unlikely to receive much benefit from broad based prevention 
efforts. Specialized prevention programmes are required for individuals who are especially 
vulnerable. These programmes are expensive but may be cost beneficial in the long term. 
5.12 Training and Service Development Issues 
The dramatic expansion of services over a short period time has left a substantial gap in the 
knowledge and experience base of many of the different professionals who have been 
newly introduced into this field. There is a need for development of a range of 
organisational and management skills for many of the key individuals within the service. 
There can be little doubt that much of the future quality of the service hinges on the 
capacity of the EHB to invest in ongoing skill development for the broad range of 
professionals involved in the service. Such an approach will require a combination of 
short-term training and workshop approaches, with a particular emphasis on training in 
team working and  
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team development. In addition there is a need for more substantial development of 
specialised professionals in the variety of disciplines involved. 
At a senior level there is a need for organisational skill development but also for 
individuals who are taking key leadership and coordinator roles to have the opportunity to 
intensify and develop specific high level skills commensurate with their roles. 
5.13 Information Strategy 
The EHB has invested in the development of a software system for the monitoring of 
clinical activity. It is clear that in the long term such a management information tool is 
required to ensure the maximum delivery of drug treatment. However, in the short term it 
is likely that there is considerable gap between current levels of information and a future 
integrated management information system. 
There is a need for prioritisation. The computerisation and linking of the pharmacists may 
be one of the initial targets, which would provide a more detailed picture of current 
pharmacy activity. 
5.14 Research 
There has been a major development of research activity, which appears to have been 
conducted primarily with the enthusiasm and good will of the clinical staff as well as one 
additional research registrar. 
Work has been done on following up a group of in-patients after discharge. In addition, 
work has been done to look at the impact of transfer to primary care. Also work has been 
done demonstrating the high levels of drug problems and problems with hepatitis C within 
the prison service. 
There is a need for a continuation and expansion of this activity in a manner, which can 
provide good data on the beneficial impact of treatment. Such an approach should involve 
a criminology perspective and an econometric perspective so that the criminal justice 
benefits can be delineated. 
6 Service response in the EHB area in the context of trends and practices elsewhere 
The following section reviews the research literature on the effectiveness of treatment for 
drug misuse to date1. Today, there remain substantial information gaps about the impact of 
treatment in several areas. The lack of current research evidence for a specific treatment is 
noted in each relevant section. 
 
                                                     
1 An on-line literature search was performed using Medline, Psychlnfo, BIDS databaselines; and Addiction 
Abstracts (1996-1999). 
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 Assessing the effectiveness of drug misuse treatment is complicated by the fact that a 
majority of individuals in need of treatment have multiple problems across personal and 
social functioning domains. Certain services are also geared towards the reduction in risk 
for particular health behaviour (e.g. needle and syringe sharing). In general positive 
outcomes from treatment include a reduction in drug use involvement, health risk 
behaviour, physical and psychological health symptoms, together with positive outcomes 
in the social functioning domains (e.g. employment, relationship problems, 
accommodation and criminal behaviour). 
The following section presents a review of the research literature on the effectiveness of 
treatment for drug misuse to 19992. Unlike the alcohol problems literature, statistical 
reviews based on pooling effect sizes reported by multiple studies of a particular 
intervention are relatively rare in the drug misuse field and reviews to date. Reviews have 
tended to be thematic in scope. It should be noted that a focused section of the kind cannot 
hope to review the research evidence for all types of treatment and the reader is encouraged 
to consult the key references for research evidence for the impact of treatment services. 
The present section focuses on more recently published information. There are substantial 
information gaps about the impact of treatment in several areas. There is a need to gather 
information on the impact of contemporary services as they are delivered on a day-to-day 
basis. Most evaluation studies have focused on the main effects of treatment for a group or 
cohort of clients. Increasingly, treatment strategists and the research community is looking 
for answers to more specific questions which concern the outcomes for priority groups, 
including groups such as young people, people with dual diagnosis, the homeless and 
people from ethnic communities. There is now a matrix of clients, treatments and referral 
and treatment management issues, which are guiding the formation of research questions. 
Assessing the effectiveness of drug misuse treatment is complicated by the fact that a 
majority of individuals in need of treatment have multiple problems across personal and 
social functioning domains. Certain services are also geared towards the reduction in risk 
for particular health behaviour (e.g. needle and syringe sharing). In general positive 
outcomes from treatment include a reduction in drug use involvement, health risk 
behaviour, physical and psychological health symptoms, together with positive outcomes 
in the social functioning domains (e.g. employment, relationship problems, 
accommodation and criminal behaviour) [1]. Whilst the primary outcome measures from 
treatment tend to be substance involvement related, a set of health, relationship 
functioning, employment and criminal indicators are usually planned by comprehensive 
outcome evaluation studies. 
 
                                                     
2 The literature search for this chapter was performed using Medline, Psychlnfo, BIDS databaselines and by consulting 
Addiction Abstracts (1996-1999). 
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 In the following sections, we review the main services and treatment interventions. 
6.1 Syringe exchange schemes 
 Quality of evidence and size of effect: II-1 (C) 
The main outcome measure for evaluating the impact of specialist and community syringe 
exchange programmes is the frequency of needle and syringe sharing incidents during the 
month prior to interview. Landmark research on the impact of the initial wave of syringe 
exchange programmes in the UK was conducted by Stimson and colleagues [2]. 
Impact studies on syringe exchange have been conducted across several countries. In 
general there is evidence from certain observational studies that, on average, participation 
in exchanges is linked to some decrease in HIV-related risks among drug injectors and that 
contact with these services was associated with a reduction in injection risk behaviour [3]. 
However, this is by no means a consistent finding [4]. HIV prevalence’ among IDUs in 
London have declined from 12.8% in 1990, to 9.8% in 1991, to 7.0% in 1992, and to 6.9% 
in 1993 and the low and stable HIV prevalence rates in several cities have been attributed, 
in part, to the early introduction of harm reduction interventions and syringe exchange 
schemes [2, 5]. Table 5-1 summarises the findings of recent studies on syringe exchange 
programmes from the international literature. 
Table 6-1: Summary of recent studies on syringe exchange programmes 
First Author Publ=n 
Year 
Study Sample Primary 
Outcome 
Measures 
Key Findings 
Durante 
[4] 
1995 National 
Survelliance 
1976 IDUs in 
1992 and 2138 
IDUs in 1993 
Sharing in 
previous month 
and proportion 
of shares 
receiving 
previously used 
needles 
Reduction of 
1.3% in sharing 
rate (95% CI - 
3.7, (1.1%) 
Proportion of 
sharers 
receiving used 
needles fell by 
18% (95% CI 
11%, 26% 
Bluthenthal 
[5] 
1998 Illegal syringe 
exchange 
programme 
1304 IDUs 
were 
interviewed, 
684 (53%) 
returned for 
more than one 
interview 
Participation in 
programme and 
sharing 
SEP use 
increased and 
syringe and 
sharing declined 
from 1992 to 
1995 
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 First Author Publ=n 
Year 
Study Sample Primary 
Outcome 
Measures 
Key Findings 
Hahn 
[6] 
1997 Syringe 
exchange 
programme 
1093 IDUs 
recruited in 
MMT out- 
patient 
detoxification 
programs in 
1998 
Risk behaviour 
and pre-needle 
exchange HIV 
serocon version 
rate 
The number of 
sharing partners 
did not change 
among IDUs 
who attended 
and sero- 
conversion 
increased 
Hagan 
[7] 
1999 Syringe 
exchange 
programme 
Cohort study 
with 647 IDUs 
Incidence of 
HBV and HCV 
No protective 
effect for HBV 
or HCV 
Collectively, syringe exchange and distribution services are likely to have contributed to public 
health efforts to achieve declining prevalence of markers of exposure to HBV in some areas of 
the UK, which is currently estimated at around 20% to 30% among London IDUs [4]. Studies in 
England show lower rates of HBV exposure among people with shorter injecting careers [8-11] 
with those starting to inject after the introduction of harm reduction interventions having 
considerably lower rates of HBV exposure than those injecting before these initiatives were put 
in place. Nevertheless, as Table 5-1 shows the research evaluation literature on the specific 
impact of the syringe exchange schemes is mixed. 
6.2 Specialist prescribing programmes (oral methadone) 
 Quality of the evidence; I-1 (B) 
Agonist prescribing (usually with oral methadone) is one of the most widely evaluated 
treatment for opioid dependence worldwide. Internationally, there is a well-established 
research and clinical evidence-base for substitution treatment with oral methadone [12, 13]. 
On average, methadone maintenance is associated with lower rates of heroin consumption, 
reduced levels of crime, and improved social functioning. A lower risk of premature 
mortality amongst maintained patients has been reported and substitution programmes have 
also contributed to the prevention of the spread of HIV infection, by encouraging change in 
injection risk-taking practices. In the UK, Results from NTORS suggests that on average, 
post treatment outcomes from opioid substitution treatments are positive across a broad 
range of substance use, injecting and needle/syringe sharing behaviours, health symptoms 
and crime measures [14]. Changes in drug use are summarised below. 
 
 
Table 6-2: Drug use at one-year follow-up (methadone clients in NTORS) 
[22] 
DRUG USE MEASURE INTAKE ONE-YEAR 
FOLLOW- 
UP 
Abstinence from illicit opioids 5% 22% 
Abstinence from stimulants 47% 64% 
Injecting illegal drugs 62% 45% 
Sharing injecting equipment 13% 5% 
Source: Gossop, Marsden & Stewart (1998); [14]. 
Data based on follow-up with 478 clients (n = 667). 
Marsch has reported the results of a statistical meta-analysis of 11 methadone maintenance 
treatment outcome studies and 8 and 24 studies investigating the effect of methadone 
maintenance treatment on HIV risk behaviours and criminal activities, respectively [15]. 
The results showed a consistent, statistically significant relationship between maintenance 
treatment and the reduction of illicit opiate use, HIV risk behaviours and drug and property 
crimes. 
Table 6-3: Unweighted effect sizes from meta-analysis of methadone maintenance 
OUTCOME DOMAIN EFFECT SIZE (R) 
Illicit opiate use 0.35 
HIV risk behaviours 0.22 
Drug-related crime 0.7 
Drug and property crime 0.23 
Drug and non-property 
Crime 
0.17 
Source: Marsch (1998) [15] 
The effectiveness of maintenance treatment appears strongest in reducing drug-related 
criminal behaviours. This treatment has a moderate effect in reducing illicit opiate use and 
drug and property-related criminal behaviours, and a small to moderate effect in reducing 
HIV risk  
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behaviours. To date there is no published evaluations that would indicate or suggestion that 
the treatment of heroin injectors is or should be substantially different from the treatment 
of heroin smokers. 
6.3 Other opioid substitution procedures 
There is increasing evidence that other opiate agonist agents such as buprenorphine and 
LAAM may have a significant role to play as alternatives to methadone in some situations 
{[13]. To date, a substantial number of randomised controlled trials have demonstrated 
similar sorts of outcomes to those on methadone, the safety profile of buprenorphine in 
relation to overdose appears to be superior to methadone and the duration of action of 
LAAM has advantages in some circumstances[13]. 
6.4 Counselling 
Quality of evidence: I-1 (B) [Structured Counselling only] 
There is widespread belief in the importance and value of counselling for opiate addicts in 
Europe and internationally [16]. However, the evidence base for the effectiveness of 
counselling with this population is sparse. Whilst there is considerable variation in the 
nature and delivery of counselling services, the English Department of Health Task Force 
to Review Services for Drug Misusers identified two main types of structured individual 
counselling which are supported by treatment service personnel: 
¾ non-directive counselling; 
¾ a range of cognitive behavioural approaches, including motivational interviewing, 
skills training and relapse prevention. 
In the broader international literature, outpatient drug-free counselling provision in the U.S. 
has been evaluated as part of the national series of field evaluation studies. Results suggest 
that abstinent oriented counselling is associated with reductions in drug use and crime 
involvement and improvements in health and well being [17,18,19]. In 1997, drug use 
outcomes for outpatient drug free programmes which contain a counselling element were 
reported by the Drug Abuse Treatment Outcome Study (DATOS) are summarised below: 
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 Table 6.4: Drug use outcomes from outpatient drug-free programmes in the 
Drug Abuse Treatment Outcome Study (DA TOS) 
OUTPATIENT DRUG-FREE 
Drug use Pre-admission year 
(n= 2,000;%) 
Follow-up year 
(n=764;%) 
Heroin 5.9 3.3 
Cocaine 41.7 18.3 
Cannabis 25.4 8.5 
Alcohol 31.0 15.1 
Source: Hubbard et al., (1997) [18] 
Note: Substance use is presented as weekly or frequent use during the one-year period 
In terms of the mediators of treatment outcome, client engagement in programme 
counselling has been reported to be a significant predictor of favorable outcome [20,21]. 
Increasing opportunities for participation by the client has been associated with greater 
treatment benefits [22]. Providing intensive, individually based, counselling to targeted 
individuals with extensive treatment histories appears to be an effective clinical strategy at 
improving outcome in outpatient drug misuse treatment [24]. 
However, overall, there is an urgent need to research [the impact of counselling] on service 
users and further research is needed to evaluate the effectiveness of different counselling 
approaches as well as models of organisation of service delivery]. 
Of all the psychosocial counselling approaches, relapse-prevention oriented, cognitive-
behavioural therapies (CBT), have received the most frequent evaluation in other countries 
[24]. Cognitive-behavioural coping skills training approaches have been used successfully 
with heroin users in assisting the prevention of relapse [25]. Several psychological 
treatments, which incorporate behavioural elements, have also produced encouraging 
results, notably contingency reinforcement therapy. [26] 
Some 24 randomized controlled trials of CBT have been conducted among adult users of 
tobacco, alcohol, cocaine, marijuana, opiates, and other types of substances [26]. In her 
review, Carroll concludes that there is good evidence for the effectiveness of CBT 
compared with no-treatment controls. The most rigorous tests of CBT therapies are 
contrasts with  
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existing treatments results have been more varied. These comparisons have led to 
somewhat mixed results in studies conducted in the US. CBT has shown encouraging 
results in the treatment of cocaine misusers. In one study, 42 clients who met DSM criteria 
for cocaine dependence were randomized to receive a 12-week programme of individual 
CBT sessions or Interpersonal Psychotherapy [27]. The trial results showed that the CBT 
subjects were more likely than subjects in the comparison condition to complete treatment 
(67 vs. 38 percent), achieve three or more continuous weeks of abstinence (57 vs. 33 
percent), and be continuously abstinent 4 or more weeks when they left treatment (43 vs. 
19 percent). Treatment gains were most evident amongst a group of severe cocaine users, 
who were more likely to achieve abstinence if assigned to receive CBT. Other studies have 
shown that CBT is effective in retaining depressed clients [28]. 
6.5 Residential Programmes 
Quality of evidence: I-1 (B) 
A relatively small number of studies have evaluated the impact of hospital inpatient units 
and residential rehabilitation programmes. One early English follow-up study of patients 
who were treated by a specialist inpatient unit found that 51% of patients were drug-free at 
a 6 months follow-up [29]. The only controlled study of in-patient and out-patient 
treatment of opiate withdrawal in the U.K. found in-patient withdrawal to be four times 
more effective (in terms of the proportion of patients who completed the withdrawal 
regime)[30]. 
For residential rehabilitation programmes, both US and UK studies have shown positive 
psychosocial benefits after treatment [31, 32]. In the US, outcome from longer-term 
residential rehabilitation programmes is related to total time spent in treatment, with 
episodes of at least three months associated with positive outcome. [33] In the US, the 
majority of studies have evaluated Therapeutic Community (TC) programmes. Programme 
length varies from short-term with aftercare to long-term programmes of over 1-year 
duration. The evidence points to the considerable success of these services for the 
recovering user sub-group. US studies show that, on average, clients receiving TC 
treatment have enduring post-discharge reductions in illicit drug use [35,36]. 
In 1989, the Treatment Outcome Prospective Study (TOPS) regular use of illicit drugs 
(weekly or more frequent consumption) was reported by 31 % of clients in the year prior to 
admission to residential programmes. For those clients who had received at least 23 months 
of treatment, this rate reduced to zero during the first 90 days of treatment, then stabilized 
across three further points: the first three months after treatment (11%); the one year after 
treatment (11%) and for the period 3-5 years post treatment (12%). In 1997, drug use 
outcomes for the long-term residential and short-term inpatient treatment modalities 
studied by the Drug Abuse Treatment Outcome Study (DATOS) are summarised below: 
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 Here results have been more varied. These comparisons have led to somewhat mixed 
results in studies conducted in the US. CBT has shown encouraging results in the treatment 
of cocaine misusers. In one study, 42 clients who met DSM criteria for cocaine dependence 
were randomized to receive a 12-week programme of individual CBT sessions or 
Interpersonal Psychotherapy [27]. The trial results showed that the CBT subjects were 
more likely than subjects in the comparison condition to complete treatment (67 vs. 38 
percent), achieve three or more continuous weeks of abstinence (57 vs. 33 percent), and be 
continuously abstinent 4 or more weeks when they left treatment (43 vs. 19 percent). 
Treatment gains were most evident amongst a group of severe cocaine users, who were 
more likely to achieve abstinence if assigned to receive CBT. Other studies have shown 
that CBT is effective in retaining depressed clients [28]. 
Table 6.5: Drug use outcomes from residential services in the 
Drug Abuse Treatment Outcome Study (DA TOS) 
 Long-term residential 
treatment 
Short-term inpatient 
Drug use Pre- 
admission 
year 
(n = 2,293; 
%) 
Follow-up 
year 
(n = 676; 
%) 
Pre- 
admission 
year 
(n = 2,613; 
%) 
Follow-up 
year 
(n = 799; 
%) 
Heroin 17.2 5.8 7.0 2.2 
Cocaine 66.4 22.1 66.8 20.8 
Cannabis 28.3 12.7 30.3 10.5 
Alcohol 40.2 18.8 48.1 19.7 
Source: Hubbard et al., (1997) [38] 
Note: Substance use is presented as weekly or frequent use during the one-year period 
In the UK, NTORS has examined outcomes after discharge from 8 inpatient units and 16 
residential rehabilitation programmes. One year follow-up results are summarised below. 
 
 
 
[27] 
Table 6-6: Drug use at one-year follow-up (residential clients in NTORS) 
Drug use measure Intake One-year 
follow-up 
Abstinence from illicit opioids 22% 50% 
Abstinence from stimulants 30% 68% 
Injecting illegal drugs 61% 33% 
Sharing injecting equipment 19% 7% 
Source: Gossop, Marsden & Stewart (1998); [39] data based on follow-up with 275 
clients 
Broekart and colleagues have reviewed seven major European country studies of the 
effectiveness of TC programmes [37J and reached the following main conclusions: 
¾ time in treatment is the most powerful predictor of positive outcome; 
¾ clients of TCs achieve major reductions in criminal involvement and increased rates 
of employment; 
¾ there is a 25% general success rate for admitted cohorts; 
¾ 85% of TC graduates (ie. those completing the main programme) had positive one 
year outcomes. 
6.6 Cost-effectiveness of drug misuse treatment 
Quality of evidence: 11-2 (C) 
There have been several cost-effectiveness studies (ie. the measurement of outcome against 
the cost of treatment) in the drug misuse treatment field, the majority having being 
conducted in the US. Health economic-relevant outcomes in the drug misuse field are 
usually conceptualised as an increase in desired, positive behaviours [40]. It is important to 
differentiate two other kinds of economic studies: cost-benefit and cost-offset. The former 
yields measures of benefit in units of monetary return [41]; the latter usually involves the 
estimation of whether the costs of drug misusers treatment is offset by reductions in 
expenditure in other health care services or in reduced victim costs due to less criminal 
involvement. 
Almost all studies which have examined changes in crime (largely acquisitive or property 
oriented) during and after an index treatment episode have shown a reduction in victim 
costs to individuals, retailers and insurers [42]. For example, the US TOPS study included 
two summary cost measures (costs to victims and cost to society) and in most instances the 
ratio of costs to benefits was quite substantial. 
[28] 
Table 6-7: Ratio of benefits to costs of treatment (TOPS) 
Impact category Outpatient 
methadone 
Residential Outpatient 
drug-free 
Costs to victims a 4.04 3.84 1.28 
Costs to society b 0.92 2.1 4.28 
Source: Hubbard et al., (1989); [38] 
a comprises a total estimate of costs to victims of crime and costs borne by  the 
criminal justice system; 
b includes estimates of costs of crime career and productivity (legitimate earnings) 
Flynn and colleagues have also reported on the costs and reduced crime-related benefits of 
long-term residential rehabilitation and outpatient drug-free treatments for cocaine 
dependence as part of the Drug Abuse Treatment Outcome Studies (DATOS) in the US 
[42]. One-year post-departure follow-up interviews with 300 residential clients and 202 
outpatient drug free clients indicated that the combined during-treatment and after-
treatment benefit to cost ratios ranged from 1.68 to 2.73 for residential treatment, and from 
1.33 to 3.26 for outpatient drug-free treatment (according to the degree of conservatism 
used for the benefit estimates employed). 
In the UK, basic economic analyses from NTORS have focused on the overall costs of 
providing treatment in relation to the costs due to crime amongst the cohort. Some 1.4 
million was estimated to have been spent in the year prior to intake to those clients who 
were followed up at one year. During this time the costs of providing drug treatments for 
these clients was approximately 3 million [14]. Reductions in criminal behavior at one year 
represented cost savings worth some 5.2 million to victims and the criminal justice system, 
leading to the conclusion that for every extra 1 spent on treatment there is a return of more 
than 3 in terms of costs savings to victims and the criminal justice system. 
6.7 Critical issues in treatment effectiveness 
Several mediating and moderating influences on the impact of treatment have been 
identified. A consistent finding from US and UK research concerns the importance of 
retention in treatment and completion of programmes which have a pre-determined 
duration. In the US, the TOPS , and DATOS studies have shown that clients who stay for 
at least 6 months on outpatient drug-free treatment and residential programmes have 
superior post-departure outcomes than those clients who have stays below this threshold; 
clients who stay for one year or more in outpatient  
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methadone treatment have substantially better outcomes than clients who leave before this 
point [44,45]. In the NTORS study the planned duration of the residential services studies 
varied considerably, and three general categories of programmes were identified: hospital 
inpatient programmes (2-5 weeks); shorter- term rehabilitation programmes (6-12 weeks) 
and longer-term rehabilitation programmes (13-52 weeks)[39]. The median number of days 
spent in treatment in these agencies by the clients in the study was 15 (inpatient); 42 (short-
term rehabilitation) and 70 (longer-term rehabilitation). Critical times in treatment which 
were associated with the greatest levels of abstinence for opiate use at one-year follow-up 
were 28 days for the inpatient and shorter-stay programmes and 90 days for the longer-
term programmes. Importantly, the percentage of clients who stayed for these critical times 
were 20% of the clients in the inpatient programmes; 64% of those in the shorter-term 
rehabilitation programmes and 40% of those treated in the longer-term programmes. 
Important advances have been made in understanding what happens during a clients stay in 
a drug misuse treatment programme. This work has sought to combine several factors, 
including a clients readiness for change (motivation), initial engagement in the programme, 
the establishment of a positive therapeutic working relationship with programme staff 
[46,47,48]. Joe and colleagues have shown that therapeutic involvement (as measured by 
rapport between a client and programme counsellor, and the clients ratings of the extent to 
which-they. are committed to treatment and believe it to be effective) and counselling 
session attributes (as measured by the number of sessions attended, the number of health 
and other topics discussed) exert direct positive effects on retention in outpatient drug-free, 
long-term residential and outpatient methadone treatment [49]. These findings are 
supported from several other valuable studies which suggest that programme counselors 
who possess strong interpersonal skills, are organized in their work, see their clients more 
frequently, refer clients to ancillary services as needed and generally establish a practical 
and empathy Atherapeutic alliance with the client [50,51,52]. 
In terms of client attributes, the presence of psychiatric comorbidity amongst drug misusers 
entering treatment has been linked to poorer outcomes [53]. Pre-treatment psychiatric 
severity to be predictive of outcome and this should be taken into account when selecting 
appropriate treatments. 
The importance of assessing the extent to which clients are ready and motivated to make 
changes in their substance use behaviors is also an important issue. Analyses from the 
DATOS datasets, for example, have shown that treatment readiness is related to retention 
and early therapeutic engagement for clients entering long-term residential treatment and 
outpatient methadone and drug-free treatments [45]. 
 
 
 
The importance of providing ancillary of wrap-around services, particularly in the first 
three months of treatment has been advocated for community-based treatment services 
[30] 
[38]. However, the intensity or comprehensiveness of services per se is not consistently 
associated with improved outcome. The matrix of client attributes and treatment factors 
and processes has important implications for referral, assessment and client treatment-
placement activities [48]. 
6.8 Urine Testing in methadone programmes 
Urine testing for illicit drugs has been a core part of methadone treatment programmes 
since their inception [54] and technology has now diversified the range of biological fluids 
that are possible to test [55]. Urine testing is primarily used for two purposes, for patient 
management and for programme evaluation. In patient management this is primarily 
around contingency contracting where take home privileges may either be gained or lost 
through test results. Overall urine testing provides an objective measure of performance 
within the limited time frame of the test. 
There has been only limited critical evaluation of the role of urine testing in reducing illicit 
drug use, Goldstein [56] conducted a study demonstrating a significant effect from testing 
but Havassy and Hall [5 7] conducted a further study which failed to demonstrate a 
reduction in illicit use with testing. 
Stitzer et al [58] have reviewed the literature on contingency management around dose 
increases, dose decreases and take home priveleges and concluded that the robust evidence 
was only for take home doses. There are some particular problems around both dose 
reduction and expulsion in that they both work against the more robust evidence of the 
benefits of retaining individuals in treatment and the role of higher doses of opiates in 
reducing illicit use. However high dosing is potentially risky in the context of alcohol and 
polydrug dependence. 
A number of studies have reported that there is major variation in how urine test results are 
used in day to day clinic practice[56, 57] ward. In addition in the modem consumer culture 
where patients are viewed as service consumers there is increasing dissonance between 
such status and the models of contingency management traditionally applied. In an 
expanded diversified treatment system service users express direct, negative critical 
commentary to programmes that implement strict surveillance and negative contingency 
management. It is possible that such programmes are more effective in reducing illicit 
opiate use but not clear whether the effect is offset by the cost of more disenfranchised and 
negative patient population. 
Some researchers now argue that urine testing can be best used to monitor programme 
effectiveness by the use of a random testing system that provides an overview of levels of 
usage within the treatment programme  
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rather than a monitoring of an individual. This is argued for on the basis of the cost savings 
in reducing the amount of urine testing and the capacity of the information to be targeted at 
improving overall management and organisational improvement. However there is no 
robust scientific consensus on the issue of urine testing. The future of testing is likely to be 
influenced by developments in the technology of testing biological specimens, the overall 
cost of testing and the voice of service users who view much of the testing in a negative 
way. 
7 Key Executive Summary and Recommendations 
7.1 The EHB has achieved a major expansion of drug services over the past five years 
and has developed innovative services. The scale of the change, growth and 
obstacles placed in the way of this change makes the achievement all the more 
remarkable. 
7.2 A programme of service expansion was embarked on that is probably one of the 
more innovative community drug service programmes in Europe. It has taken the 
core of the evidence on the effectiveness of methadone maintenance and attempted 
to develop a range of services to ensure higher levels of treatment access. This has 
resulted in a major expansion in the levels of provision of methadone treatment with 
over 4000 individuals in treatment by October 1999. 
7.3 The introduction of the Methadone Protocol has enabled the formal organisation of 
the relationship between primary care and secondary care delivery of methadone 
treatment. At the same time the Pharmacy Coordinators have developed a large 
network of community pharmacists who are trained and experienced in the delivery 
of services to drug misusers. Over 50 different treatment sites have been established 
with a mixture of larger on site services such as Castle St and St James Hospital to 
smaller satellite clinics in North, South and West County Dublin. 
7.4 It is appropriate to state that by international standards of assessment of methadone 
clinics the rates of both positive and negative opiate tests indicate clinics that are 
operating to a very high standard of performance on this particular parameter. 
However, on the negative side the high rates of benzodiazepine positivity indicate a 
major problem of polydrug misuse, which requires urgent and concerted attention. 
7.5 A number of the satellite clinics informally reported rates of 40% plus returning to 
work, such levels of beginning or returning to work indicate the positive work 
climate that exists in Dublin but is also very striking as evidence of successful social 
habilitation or rehabilitation. It is worth further exploring these variations to 
determine whether program or clinic characteristics are associated or facilitate these 
positive outcomes. Rates of 30% return to work are remarkable by current 
international standards and full attention should be paid to this phenomenon. A 
process should be put in place to properly monitor and document the performance of 
the clinics 
[32] 
  on this parameter. Such an exercise should formally establish through documented 
and objective procedures the social welfare and occupational status of individuals in 
treatment. 
7.6 Thus, the services have expanded from three locations to over 50 locations in the 
space of a five years. Over the past decade the budget for the service has increased 
more than 10 fold. This level of rapid expansion is a major achievement that 
involves an all-consuming level of managerial and administrative involvement. The 
services are now likely to require an opportunity for consolidation and planning for 
the next level of development. 
7.7 The staff of all the different services demonstrate a high level of commitment to 
developing and improving on existing service provision. There is a high level of 
pride and a high sense of achievement among staff. 
7.8 The level of change and the demands made on many staff leave the system under 
pressure and there is a need to ensure that the coordination, support and liaison 
functions are further developed in a manner that ensures sustainable level of 
professional commitment to day to day work. 
7.9 The services have expanded rapidly and much of the organisations time has been 
taken up with prolonged community consultation which was necessary and is 
required on an ongoing basis. However, such activity needs to be balanced by 
detailed work within the services building up more coherent team functioning and 
ensuring adequate support for team members in working with a damaged and 
difficult treatment population. 
7.10 In addition to further developing multidisciplinary team working, there is a case for 
considering the development of a key worker or alternatively a case manager system 
that attempts to ensure that the needs of an individual patient can be 
comprehensively addressed through combining the skills of the range of disciplines 
working within the service. 
7.11 Within the primary care service there is a need to ensure that coordinators develop 
the support to level one general practitioners in a manner that increases the level of 
take up of patients by level one general practitioners and, thereby, increases the 
capacity of the treatment service. 
7.12 The EHB should consider choosing a range of key performance parameters and 
ensure that data on these parameters are collected and analysed across the entire 
service. 
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7.13 There is a need for an urgent audit of benzodiazepines within the service. This 
should involve auditing of prescribing within the drug services and also of 
prescribing by practitioners who are not involved in the drug services. The 
Department of Health should be involved and action may need to be taken to restrict 
benzodiazpine prescribing if the current high levels of misuse are to be contained. 
7.14 Between January 1999 and October 1999, 205 new patients went into primary care 
services. While this appears modest as a number it’s a significant proportionate 
increase in numbers in primary care. However, it is clear that there needs to be a 
substantial increase in this if the capacity problem across the service is to be 
adequately addressed. There were 119 general practitioners involved in the protocol 
at the end of October 1999, but of these 71 practitioners had less 5 patients with 
nearly half having less than three patients. There is a need to expand the number of 
practitioners and encourage and support these practitioners to manage a reasonable 
workload of patients. Issues on this are discussed in the next section. 
7.15 Within this approach there is also a need to consider briefer management approaches 
as exemplified in the Fortune House Project, where detoxification over a shorter 
period of time is delivered. Such an approach would allow for people with a shorter 
history of opiate dependence to attempt to achieve a drug free status and it would 
also be clear that multiple failed attempts at such an approach should lead to 
consideration of more sustained maintenance treatment. A twin track approach that 
combines detoxification with maintenance would also ensure some individuals could 
have shorter-term contact with services. This would in effect create some treatment 
capacity by having a degree of throughput for one stream of patients. 
7.16 Overall it is clear that in most of these settings the teams have managed rapidly 
increasing work loads with enthusiasm, skill and commitment. However, there is 
considerable duplication of function and overlap of function within teams when it 
comes to the management of individual clients. Consideration should be given to the 
development of a key worker system where a single individual worker in the team 
would be responsible for the treatment of an individual who would be subject to 
overall team review. 
7.17 The other possible option that could be considered is the use of care coordinators or 
case managers. Such individuals could be tasked with overseeing the delivery of 
multimodal treatment from a range of professionals and also assessing the impact of 
such treatment against baseline measures. Such an approach might assist in ensuring 
better coordination and integration of services. Of course, such an approach would 
be contingent on the availability of a range of services and on the ready access of 
such services for these patients. 
7.18 Given the integrated nature of EHB services there seems to be a strong case for 
substantial expansion in this form of liaison/shared care model into primary care, 
general mental health services, child and adolescent psychiatric services, hepatology 
services, and criminal justice agencies. At a local level, case managers or liaison 
workers could provide a key role in ensuring that a combination of community and 
statutory resources are  
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mobilised in order to achieve maximum treatment and rehabilitation impact. 
7.19 There is also a need for a network of needle exchange facilities that could provide 
sterile syringes as well as collect used equipment. It is possible that pharmacies have 
an important role to play in this and could be engaged without encountering major 
issues of community resistance that may be likely with the development of other 
facilities. 
7.20 A well evaluated pilot study of needle exchange via community pharmacy would be 
a rational and practical way forward which would provide useful information about 
processes and problems in establishing such a service. 
7.21 There have been very major developments in the delivery of services to drug users 
through pharmacy based services over the past five years. The Pharmacy co-
ordinators faced a substantial challenge in developing community pharmacy based 
services and has achieved remarkable success. There is a clear need for ongoing 
training and support and there may be room for developing innovative modes of 
communication between the clinicians in the drug services and the pharmacies that 
would improve the overall function of the team. Better integration between these 
professionals is likely to pay substantial dividends in the quality and coherence of 
the local service. 
7.22 There is now a need to broaden the base of services available and to consider how 
briefer types of interventions could be developed that would be accessible for young 
people before they have progressed to chronic heroin addiction. A broader 
community based treatment programme where the workers have a capacity to 
conduct assessments and provide advice and treatment for problems ranging from 
long term cannabis use, MDMA, cocaine and benzodiazepines is required. To date, 
some of this has been provided by counsellors, outreach workers and others. There is 
a need to formalise this approach and it is possible that such an approach could be 
provided on a larger geographical scale than current clinic provision. Such an 
approach could be based on a direct access system and problems of a more complex 
nature could be referred to more local services. 
7.23 Currently the Voluntary Sector Residential services continue to be key providers of 
services. Many of these services are long standing with experienced and 
knowledgeable staff, however, there is a need for these different services to meet 
and to develop a more cohesive voice about the role of the residential sector in the 
overall provision of services. Such joint activities could also explore issues of 
training and establishing mutually agreed standards for service provision. In 
particular, there is a need for a more coherent approach to how these services link 
into the broader range of community services. 
 
 
[35] 
Acknowledgements 
Special thanks, in particular, go to Martin Gallagher, James Conway and Geraldine Murtagh for 
their constant help and support with this project. Thanks also to all key individuals from all the 
various areas of services who generously provided their time and thoughts on future 
developments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[36] 
References 
1. Stimson, G.V. (1996) Has the United Kingdom averted an epidemic of HIV-1 infection among drug 
injectors? Addiction, 91, 1085-1088. 
2. Des Jarlais, D.C., Hagan, H., Friedman, S.R., Friedmann, P., Goldberg, D., Frischer, M., Green, S., 
Tunving, K., Ljungberg, B., Wodak, A., Ross, M., Purchase, D., Millson, M.E., & Myers, T. (1995) 
Maintaining low HIV seroprevalence in populations of injecting drug users. Journal of the American 
Medical Association, 274, 1226-1231. 
3. Drucker E., Lurie P., Wodak A. & Alcabes, P. (1998) Measuring harm reduction: the effects of 
needle and syringe exchange programs and methadone maintenance on the ecology of HIV. AIDS. 
12SupplA:S217-30 
4. Durante AJ., Hart GJ. Brady AR. Madden PB. & Noone A. (1995) The Health of the Nation target 
on syringe sharing: a role for routine surveillance in assessing progress and targeting interventions, 
Addiction, 90, 1389-1396. 
5. Bluthenthal RN. Kral A.H., Erringer E.A., & Edlin BR. (1998) Use of an illegal syringe exchange 
and injection-related risk behaviors among street-recruited injection drug users in Oakland, 
California, 1992 to 1995. Journal of Acquired Immune Deficiency Syndromes, 18, 505-11. 
6. Hahn JA., Vranizan KM. & Moss AR. (1997) Who uses needle exchange? A study of injection drug 
users in treatment in San Francisco, 1989-1990, Journal of Acquired Immune Deficiency 
Syndromes, 15, 157-64, 
7. Hagan, H., McGough, J.P., Thiede, H., Weiss, N.S. & Hopkins, S. (1999) Syringe exchange and risk 
of infection with hepatitis B and C viruses, American Journal of Epidemiology, 149, 214-216. 
8. Judd A, Hunter G, Maconochie N, Hickman M, Parry J, Renton A, Stimson G. (1999) HIV 
prevalence and risk behaviour among female injecting drug users in London, 1990 to 1996, AIDS, 
13, 833-837. 
9. Hunter, G., Stimson, G.V., Jones, S., Judd, A., & Hickman, M. (1998) Survey of prevalence of 
sharing by injecting drug users not in contact with services: An independent study carried out on 
behalf of the Department of Health, London: Centre for Research on Drugs and Health Behaviour. 
10. Rhodes, T., Hunter, G.M., Stimson, G.V., Donoghoe, M.C., Noble, A., Parry, J., & Chalmers, C. 
(1996) Prevalence of markers for hepatitis B virus and HIV-1 among drug injectors in London: 
injecting careers, positivity and risk behaviour. Addiction, 91, 1457-1467. 
11. Unlinked Anonymous Surveys Steering Group (1997) Prevalence of HIV in England and Wales in 
1996. Annual report of the Unlinked Anonymous Prevalence Monitoring Programme, London: 
Department of Health. 
12. Ward, J., Mattick, R.P. and Hallm W. (1992) Key issues in methadone maintenance treatment. 
Sydney: New South Wales University Press. 
13. Ward, J. Mattick, R.P. & Hall, W. (eds.) 1998 Methadone maintenance treatment and other opioid 
replacement therapies. Amsterdam: Harwood Academic Publishers. 
14. Gossop, M., Marsden, J., & Stewart, D. (1998) National Treatment Outcome Research Study: 
NTORS at one-year. London: Department of Health. 
15. Marsch, L.A. (1998) The efficacy of methadone maintenance interventions in reducing illicit opiate 
use, HIV risk behavior and criminality: a meta-analysis. Addiction, 93, 515-32 
[37] 
16. Task Force Report (1995) An Independent Review of the Effectiveness of Treatment for Drug 
Dependence. Department of Health. London 
17. Hubbard, R.L., Craddock, S.G, Flynn, P.M., Anderson, J., & Ehteridge, R. (1997) Overview of 1-
year follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS), Psychology of 
Addictive Behaviours, 11, 261-278. 
18. Simpson, D.D & Sells, S.B. (Eds.) (1990) Opioid addiction and treatment: A 12-year follow-up. 
Malabar, FL: Keiger. 
19. Ball, J. & Ross, A. (1991) The Effectiveness of Methadone Maintenance Treatment. New York: 
Springer. 
20. Fiorentine, R. & Anglin, D. (1997) Does increasing the opportunity for counseling increase the 
effectiveness of outpatient drug treatment? Journal of Substance Abuse Treatment, 23, 369-382. 
21. Hser, Y., Grella, C.E., Hsieh, S., Anglin, M.D.& Brown, B.S. (1999) Prior treatment experience 
related to process and outcomes in DATOS. Drug and Alcohol Dependence, 57, 137-150. 
22. Joe, G.W., Simpson, D.D. & Hubbard, R.L. (1991) Treatment predictors of tenure in methadone 
maintenance, Journal of Substance Abuse, 3, 73-84. 
23. General Accounting Office. Cocaine Treatment: Early Results From Various Approaches. 
Washington, DC: GAO, 1996. 
24. Saunders, B., Wilkinson, C. & Phillips, M. (1995) The impact of a brief motivational intervention 
with opiate users attending a methadone programme, Addiction, 90, 415-424. 
25. Higgins, S.T., Budney, A.J., Bickel,-W.K., Badger, G.J., Foerg, F.E.& Ogden, D. (1995) Outpatient 
behavioural treatment for cocaine dependence, Experimental and Clinical Psychopharmacology, 3, 
205-212. 
26. Carroll, K.M. (1996) Relapse prevention as a psychosocial treatment approach: A review of 
controlled clinical trials. Experimental and Clinical Psychopharmacology 4, 46-54. 
27. Carroll, K.M.; Rounsaville, B.J.; & Gawin, F.H. (1991) A comparative trial of psychotherapies for 
ambulatory cocaine abusers: Relapse prevention and interpersonal psychotherapy . Am J Drug 
Alcohol Abuse, 17, 229-247. 
28. Carroll, K.M.; Nich, C.; and Rounsaville, B.J. Differential symptom reduction in epressed cocaine 
abusers treated with psychotherapy and pharmacotherapy (1995). Journal of Nervous and Mental 
Disease, 183,251-259. 
29. Gossop, M., Green, L., Phillips, G. and Bradley, B. (1989) Lapse, relapse and survival among opiate 
addicts after treatment, British Journal of Psychiatry, 154, 348-353. 
30. Gossop, M., Johns, A., & Green, L. (1986) Opiate withdrawal: in-patient versus outpatient 
programmes and preferred versus random assignment to treatment. British Medical Journal, 293, 
697-699. 
31. DeLeon, G. & Jainchill, N. (1982) Male and female drug abusers: Social and psychological status 
two years after treatment in a therapeutic community. American Journal of Drug and Alcohol 
Abuse, 8, 465-497. 
32. Bennett, G. & Rigby, K. (1990) Psychological change during residence in a rehabilitation centre for 
female drug misusers. Part I. Drug misusers. Drug and Alcohol Dependence, 27, 149-157. 
[38] 
33. Simpson, D.D. (1997) Effectiveness of drug abuse treatment: A review of research from field 
settings. In J. Egertson, D.Fox, & A. Leshner (eds). Treating drug abusers effectively. Oxford: 
Blackwell. 
34. Gossop, M., Marsden, J., Stewart, D. & Roife, A. (in press) Time in residential treatment 
programmes and outcomes at one year: results from the national treatment outcome research study. 
Drug and Alcohol Dependence. 
35. DeLeon, G., Andrews, M., Wexler, H., Jaffe, J. & Rosenthal, M. (1979) Therapeutic community 
dropouts: Criminal behaviour five years after treatment. American Journal of Drug and Alcohol 
Abuse, 6, 253-271. 
36. Simpson, D. & Lloyd, M.R. (1979) Client evaluation of drug abuse treatment in relation to follow-
up outcomes. American Journal of Alcohol Abuse, 6, 397-411. 
37. Broekaert, E., Raes, V., Kaplan, C.D. & Coletti, M. (1999) The design and effectiveness of 
therapeutic community research in Europe: an overview. European Addiction Research, 5, 21-35. 
38. Hubbard, R.L., Craddock, S.G., Flynn, P., Anderson, J., Etheridge, R.M.. (1997) Overview of 1-year 
outcomes in the drug abuse treatment outcome study (DATOS), Psychology of Addictive 
Behaviours, 11,261-278. 
39. Gossop, M, Marsden, J., Stewart, D. & Rolfe, A. (1999) Treatment retention and 1 year outcomes 
for residential programmes in England. Drug and Alcohol Dependence, 57, 89-98. 
40. Plotnick, R. (1994) Applying benefit-cost analysis to substance abuse prevention programs. 
International Journal of the Addictions, 29, 339-359. 
41. Gerstein, D.R., Johnson, R.A., Harwood, H.J., Suter. N. & Malloy, K. (1994) Evaluating Recovery 
Services: the California Drug and Alcohol Treatment Assessment (CALDATA). Sacramento, CA: 
California Department of Alcohol and Drug Programs. 
42. Flynn, P., Kristiansen, P.L., Porto, J.V. & Hubbard, R.L. (1999) Costs and benefits of treatment for 
cocaine addiction in DATOS. Drug and Alcohol Dependence, 57, 167-174. 
43. Lovejoy, M., Rosenblum, A., Magura, S., Foote, J., Handelsman, L., & Stimmel, B. (1995) 
Patients= perspectives on the process of change in substance abuse treatment. Journal of Substance 
Abuse Treatment, 12, 269-282. 
44. Simpson, D.D., Joe, G.W., Rowan-Szal, G. & Greener, J. (1995) Client engagement and change 
during drug abuse treatment. Journal of Substance Abuse, 7, 117-134. 
45. Joe, G.W., Simpson, D.D. & Broome, K.M. (1999) Retention and patient engagement models for 
different treatment modalities in DATOS. Drug and Alcohol Dependence, 57, 113-125. 
46. Luborsky, L, McLellan, A.T., Woody, G.E., O=Brien, C.P & Auerbach, A. (1985) Therapist success 
and its determinants. Archives of General Psychiatry, 42, 602-611. 
47. Najavits, L.M. & Weiss, R.D. (1994) Variations in therapist effectiveness in the treatment of 
patients with substance use disorders: An empirical review, Addiction, 89, 679-688. 
48. McLellan, A.T., Luborsky, L., Woody, G.E. et al. (1983) Increased effectiveness of substance abuse 
treatment: A prospective study of patient-treatment matching, Journal of Nervous and Mental 
Disease, 171, 597-605. 
49. Joe, G.W., Simpson, D.D. & Broome, K.M. (1998) Effects of readiness for drug abuse treatment on 
client retention and assessment of process. Addiction, 93, 1177-1190. 
[39] 
50. Etheridge, R.M., Craddock, S.G., Dunteman, G.H., & Hubbard, R.L. (1995) Treatment services in 
two national studies of community-based drug abuse treatment systems. Journal of Substance Abuse 
Treatment, 7, 9-26. 
51. Florentine, R. & Anglin, D. (1996) More is better: counselling participation and the effectiveness of 
outpatient drug treatment. Journal of Substance Abuse Treatment, 13, 241-248. 
52. McLellan, A.T., & Wisner, C. (1996) Achieving the public health potential of substance abuse 
treatment: implications for patient referral, treatment >matching= and outcome evaluation. In: W. 
Bickel & R. DeGrandpre (eds.) Drug Policy and Human Nature, Philadelphia, PA: Wilkins & 
Wilkins. 
53. Scott, J., Gilvarry, E., & Farrell, M., (1998) Managing anxiety and depression in alcohol and drug 
dependence. Addictive Behaviours, 23, 919-931. Trellis ES, Smith FF, Alston DC and Siassi I 
(1975) The pitfalls of urine surveillance: the role of research in evaluation and remedy. Addictive 
Behaviours, 1, 83-88. 
54. Trellis ES, Smith FF, Alston DC and Siassi I (1975) The pitfalls of urine surveillance: the role of 
research in evaluation and remedy. Addictive Behaviours, 1, 83-88. 
55. Wolff K, Farrell M, Marsden J, Ali R, Monteiro M, Welch S, Strang J (1999) Biological indicators 
of drug use and misuse: a review. Addiction. 
56. Goldstein A, Horns WH, and Hansteen RW (1977) Is on-site urine testing of therapeutic value in a 
methadone treatment programme.? International Journal of the Addictions,12, 717-728. 
57. Havassy B and Hall S (1981) Efficacy of urine monitoring in methadone maintenance treatment. 
American Journal of Psychiatry, 138, 1497-1500. 
[40] 
